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Abstract
Background: The comparative effectiveness (CE) of endoscopic screening (versus no screening) for Barrett’s
esophagus (BE) in patients with GERD symptoms, or among different endoscopic surveillance strategies in patients
with BE, for the early detection of esophageal adenocarcinoma (EA) is unknown. Furthermore, it is unclear if
patients or providers have or will adopt any of these strategies (screening only, screening and surveillance,
vs. none), irrespective of their effectiveness. Endoscopic screening and surveillance is expensive and can be risky.
Therefore, it is imperative to establish the CE and acceptability about the risks and outcomes related to these
practices to better inform expert recommendations and provider-patient decisions.
Methods/Results: We propose a mixed methods study which will involve: (1) an analysis of secondary databases
(VA and VA-Medicare linked datasets for 2004–09) to examine CE of endoscopic screening and surveillance in an
observational study cohort (an estimated 680,000 patients with GERD; 25,000–30,000 with BE; and 3,000 with EA);
(2) a structured electronic medical record (EMR) review on a national sample of patients using VA EMRs to verify all
EA cases, identify cancer stage, cancer-targeted therapy, and validate the screening and surveillance endoscopy;
and (3) qualitative in depth interviews with patients and providers to elicit preferences, norms, and behaviors to
explain clinical contexts of these findings and address gaps arising from the CE study.
Conclusion: This study will compare clinical strategies for detecting and monitoring BE, a pre-cancerous lesion.
Additionally, by eliciting acceptability of these strategies for patients and providers, we will be able to propose
effective and feasible strategies that are likely to be implemented in routine use. Findings will inform
recommendations for clinical practice guidelines. Our innovative approach is consistent with the methodological
standards of patient-centered outcomes research, and our findings will offer a significant contribution to the
literature on cancer surveillance.
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Background
Esophageal adenocarcinoma (EA) is one of the fastest
rising cancers in the United States [1-3]. The rise has
been most dramatic among white men, with a five-fold
increase between 1980 and 2005 [2,4]. EA is a highly
fatal cancer with a median survival of less than one year
following diagnosis [5]. Barrett’s esophagus (BE) is a de-
tectable precursor lesion that offers a potential target for
preventing EA. The risk of EA in individuals with BE is
increased between 30 and 130-fold as compared to gen-
eral population controls [6]. The annual incidence of EA
in BE is estimated to be 0.5%. The onset of BE is silent,
and therefore its exact time of onset is virtually never
known. Elderly Caucasian men in developed countries
have the highest risk of BE [7,8]. The presence of frequent
chronic gastroesophageal reflux disease (GERD) symp-
toms has been consistently associated with an increased
risk of BE as well as EA [9,10].
Current practice guidelines advocate endoscopic screen-
ing for adult individuals with chronic GERD symptoms
[11]. Once BE is diagnosed, endoscopic surveillance is
recommended [11-13]. The detection of early neoplastic
changes (dysplasia or carcinoma in situ) prompts treat-
ment with several potentially curative modalities of local
ablation or esophageal resection [8,12-15]; the predicted
benefit being reduction of EA incidence by treating BE
with dysplasia, and improving EA outcomes.
Effectiveness of screening and surveillance endoscopy
is highly dependent on the utilization of these proce-
dures. However, the extent and patterns of endoscopic
screening and surveillance in practice are unclear. Phys-
ician surveys indicate that more than 95% of gastroen-
terologists recommend BE surveillance [16]. There are
no large-scale studies from community or healthcare
system based settings documenting the use of screening
or surveillance endoscopy among well-defined popula-
tions. Studies evaluating patients’ perceptions of cancer
risk and acceptability of endoscopic surveillance for BE,
and predictors of adherence to surveillance endoscopy
demonstrate poor understanding of the available evi-
dence and utilization that is driven by insurance type
and availability of endoscopy services [17-22].
The comparative effectiveness (CE) of screening endos-
copy (vs. no screening) in patients with upper GI symp-
toms, surveillance (vs. no surveillance) in BE patients, and
CE of different surveillance strategies (frequency, inten-
sity) is unclear due to a lack of evidence-based findings for
GERD/BE populations at risk of EA. Existing studies
examining the effectiveness of screening and surveillance
endoscopy generally fall into one of two categories:
(1) large retrospective population-based studies in which
researchers examine EA patients’ charts for the presence
of pre-diagnosis endoscopy and then form associations be-
tween endoscopy and stage of cancer at the time of
diagnosis and treatment and survival following diagnosis;
these studies have the uniform limitation of not examining
the population at risk (GERD or BE), or (2) small studies
of BE patients with relatively short follow up and very few
EA cases. Though they provided information on the pos-
sible role of endoscopy in affecting the outcomes of EA,
past studies have not addressed the frequency or yield in
the population at risk. There have been no cohort studies
addressing CE of screening or surveillance endoscopy in
populations at risk. We propose to conduct such a CE
study.
While there is limited knowledge about effectiveness
of various EA screening and surveillance strategies, less
is known about factors that shape physicians’ and
patients’ decisions concerning such strategies. Patients’
decisions to participate in initial screening, repetitive
surveillance, or treatment may be guided by their per-
ceptions of cancer risk, their expected outcomes of par-
ticipation, and by other affective responses to screening
and surveillance experiences and norms. Risk perception
is defined as the assessment of one’s personal risk for
cancer diagnosis and cancer-related mortality. Most
patients with BE incorrectly estimate their risk of EA.
Shaheen et al. performed a study evaluating the risk per-
ceptions for progression to EA among 118 patients with
non-dysplastic BE undergoing surveillance endoscopy
[22]. The study, which used a visual analog scale that
was developed to factor low incidence risks [23], found
that 68% of respondents over-estimated their 1-year risk
of cancer (13.6% versus an actual risk of 0.05%) [22]. In
contrast, a Dutch study of 192 patients with BE and no
high-grade dysplasia found that participants underesti-
mated their 1-year risk of cancer [21]. Taken together
these data underscore the notion that patients with BE
may not pursue screening and surveillance behaviors
based on inaccurate perceptions of cancer risk. No data
is available to accurately estimate physicians’ risk per-
ceptions or describe how physicians and patients discuss
and reach consensus on the benefits and risks of endo-
scopic surveillance.
Physicians often over-appreciate the benefits of diag-
nosing BE. It has been suggested that physicians largely
do not balance the real social harms and costs of diag-
nosing BE against the potential benefits of cancer pre-
vention. A diagnosis of BE alone was found to double
health and life insurance premiums across a wide range
of surveyed national insurance companies [24]. Sparse
data exists to inform physicians’ outcome expectancies
for surveillance and ablative therapy. Some clinical and
decision science experts have even advocated against
surveillance (while still supporting screening) due to the
significant limitations, uncertain benefits, and potential
costs [25-27]. Better evidence is needed to clarify how phy-
sicians perceive the quantitative and qualitative benefits/
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risks of surveillance and therapeutic endoscopy and how
such information is communicated to patients to arrive at
informed decisions.
In light of the many gaps in knowledge regarding the
extent of utilization and perceptions of endoscopic
screening and surveillance, the CE of various strategies,
and the patient and provider factors that shape decisions
to adopt current and future practice guidelines, we
propose to conduct a study with the following specific
aims. In this article, screening endoscopy is defined as
endoscopy in patients with no known BE or EA, while
surveillance is endoscopy in patients with known BE.
Specific aims
Comparative effectiveness aims
To compare the risk (detection rate) and outcomes (stage,
treatment, survival) of EA among patients undergoing dif-
ferent intensities of screening and surveillance endoscopy.
We hypothesize that screening (vs. none) and surveillance
endoscopy (once every 2 years, or once every 3 years vs.
none) will increase the likelihood of patients: being diag-
nosed with early stage EA; receiving treatments for EA;
and having lower EA-specific mortality.
To identify predictors of desired outcomes of EA (low
incidence and low EA mortality). Potential predictors in-
clude demographic features (e.g. age), GERD features
(e.g. duration), interventions (e.g. PPI, fundoplication, ab-
lation), and other BE risk factors (e.g. obesity, smoking).
Qualitative aim
To elicit physicians’ and patients’ risk perceptions, out-
come expectancies, and affective responses to endo-
scopic screening and surveillance strategies and ablative
therapy. Using an integrated model of decision making
and health behavior, we will describe how these various
perceptions potentially effect adoption and implementa-
tion of surveillance endoscopy.
Methods
Design overview
To address these aims, we propose a study with a mixed
methods approach where we will (1) use secondary data-
bases (VA and VA-Medicare linked datasets for 2004–09)
to examine CE of screening and surveillance in an ob-
servational study cohort (an estimated 680,000 patients
with GERD, 25,000–30,000 with BE, and 3,000 with EA);
(2) conduct a detailed structured electronic medical rec-
ord (EMR) review on a national sample of patients using
VA electronic medical records to verify all EA cases, iden-
tify cancer stage, cancer-targeted therapy, and validate
screening and surveillance endoscopy; and (3) generate
qualitative data from in-depth interviews on patient and
provider preferences, rationale, and behavioral utilities to
explain some of the findings from the cohort study and
inform the recommendations resulting from this research.
This human subjects study was approved by the Institu-
tional Review Board of Baylor College of Medicine (Com-
parative Effectiveness of Screening and Surveillance
Endoscopy, protocol H-27619).
Comparative effectiveness aim
Data for this aim will come from the Austin Information
Technology Center (AITC). The AITC houses several
administrative datasets for the VA, including: Medical
SAS Inpatient and Outpatient files, Decision Support
System (DSS) files, and the Vital Status File. The SAS In-
patient and Outpatient files provide detailed patient
demographic characteristics, such as date of birth and
race/ethnicity, as well as procedure (CPT codes) and
diagnosis (ICD-9 codes) codes from inpatient and out-
patient visits. The DSS includes select laboratory test
results and pharmacy information. The Vital Status File
contains patients’ date of death. VA-Medicare is a linked
file of all Medicare claims made by VA users. This file
will be used to ascertain additional information for
Medicare eligible (mostly 65 years and older) patients
who may have co-utilized services outside the VA. We
will also perform structured chart abstraction of the VA
EMR on all patients with EA in the VA nationwide and
a random sample of patients with screening and surveil-
lance endoscopy with GERD and/or BE. We will access
the EMRs using Compensation and Pension Record
Interchange (CAPRI), a VA application that provides ac-
cess to the EMR found in the Computerized Patient
Record System (CPRS) at any VA facility nationwide.
Participants
Patient participants include approximately 680,000 veter-
ans with GERD, 25,000-30,000 with BE, and 3,000 with
EA. These patients will all be veterans enrolled in the VA
healthcare system. A waiver of consent and authorization
has been approved by the local IRB for this aim of the
protocol.
Inclusion criteria
We will include patients between 18 and 90 yrs old with
GERD and/or BE. Patients with GERD will be identified in
the outpatient VA files during 2003–09 with a one in-
patient or two outpatient ICD-9 codes for GERD. Patients
with BE will be defined by the presence of ICD-CM-9
code 530.85 combined with at least one EGD test (CPT
codes 43200–43259, excluding 43246) within 12 months
after the BE code date.
Exclusion criteria
In order to identify candidates for surveillance, we will ex-
clude those with any gastric duodenal or esophageal can-
cers, abdominal surgery, decompensated liver disease,
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feeding tube, any metastatic cancer, or chemotherapy.
These patients will be identified by related ICD-9 codes
within 5 years preceding BE index date. To maximize the
likelihood of having new GERD diagnosis, we will also ex-
clude patients with previous GERD diagnosis preceding
GERD index date during the study period.
Study variables
Exposure: endoscopy procedures recorded in the study
cohort will be classified as screening, surveillance, or
diagnostic endoscopy. We define that (1) Screening en-
doscopy is the first non-diagnostic endoscopy recorded
after the index date for GERD; (2) Surveillance endos-
copy is any non-diagnostic endoscopy performed in
patients with BE (after the screening endoscopy where
BE is diagnosed); and (3) Diagnostic endoscopy is
any endoscopy performed in patients with “alarm” fea-
tures in the 1 year preceding endoscopy date; these in-
clude low hemoglobin and anemia (Hgb <12 g/dl, and
<8.5 g/dl, respectively), dysphagia, and GI bleeding
(hemetemsis, melena, hematochezia), and any of the ex-
clusion criteria mentioned above that may develop after
the GERD index date.
Follow up: All patients in the cohort will have follow
up till death, development of EA, or end of study period
in 09/30/2011.
Outcomes: 1) EA diagnosis based on a structured
EMR review for diagnosis and treatment related to EA
where EA is defined based on endoscopic and histo-
logical criteria; 2) EA stage as determined from tumor
board or results of diagnostic tests; 3) any receipt of EA
treatment; 4) EA related death.
Potential Confounders and Effect Modifiers: Confound-
ing factors, observed and unobserved, can affect each
process over the follow-up periods and may generate
biases that affect the main study estimates. The below
variables will be considered as potential confounders.
Patient Factors: Socio-demographic factors, including
age, gender, race, ethnicity, marital status, and socioeco-
nomic status. VA priority levels will be used as a surro-
gate for socioeconomic status. Clinical characteristics
will include medical and psychiatric comorbidities. We
will also evaluate filled prescriptions for medications (e.g.
PPI or H2-receptor antagonists) including measures of ad-
herence (medication-ownership ratio) and persistence
(length of therapy, fill-refill ratio, and discontinuation rate)
[28-30], BE risk factors (e.g., BMI, smoking), BE treatment
(photodynamic therapy, mucosal resection, radiofrequency
ablation, or cryoablation), and the presence of dysplasia.
Non-Patient Factors: We will identify the VA facility
for each patient following the date of GERD or BE diag-
nosis. Facility factors will include urban or rural setting,
regions, academic affiliation, overall patient load, and
GERD and BE load. We will examine provider type by




We will conduct one-on-one in-depth interviews with a
targeted sample of up to 70 individuals (45 patients and
25 physicians) who meet the specified inclusion criteria.
One-on-one interviews are useful for exploring indivi-
duals’ opinions, and are designed to render stories and
provide information depth [31]. We chose the sample
size of 70 because it is expected to generate sufficient
data to perform a qualitative analysis of patients’ and
physicians’ beliefs and corresponding decisions regarding
screening, surveillance, and treatment for GERD and
various degrees of BE (i.e. BE with high grade dysplasia,
BE with low-grade dysplasia, BE without dysplasia). All
interviewees will provide written consent prior to par-
ticipation and all interviews will be recorded, tran-
scribed, and analyzed for content.
We will apply a stratified purposeful sampling tech-
nique to recruit patients who meet the criteria for three
categories of interest, including: 1) patients with GERD
who are scheduled to undergo their first ever endoscopy
(see Additional file 1: Appendix I), 2) patients who have
been diagnosed with BE (with or without dysplasia), and
3) patients who have been diagnosed with BE and have
undergone at least one ablation (see Additional file 1 II
for the later two categories). The stratified purposeful
sampling strategy allows for the sampling of subgroups
and facilitates comparisons between the subgroups [32].
We will review EMRs from the Michael E. DeBakey VA
Medical Center (MEDVAMC) to identify patients trea-
ted at the MEDVAMC gastroenterology specialty clinic,
and we will identify physicians using the list of prac-
ticing gastroenterologists in three local GI practices, in-
cluding one VA hospital.
Patient interviews will elicit information about etio-
logical understandings of their condition (GERD or BE),
reactions to their GERD or BE diagnosis, beliefs and
expectations about endoscopy, perceptions of risk of
developing EA, barriers and facilitators of undergoing
endoscopy, and beliefs and expectations about ablative
therapy, if relevant. Interview guides will be tailored for
the three categories of interest described above (See
Appendices I and II). We will also conduct individual,
in-depth interviews with up to 25 gastroenterologists to
obtain information about their experiences with screening
and surveillance endoscopy in patients with GERD and/or
BE (see Additional file 1: Appendix II). Interviews will elicit
information about physicians’ screening, surveillance, and
ablation practices, their beliefs about EA risk, perceptions
of effectiveness of screening and surveillance endoscopy,
and their perceptions of patients’ beliefs. We will conclude
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sampling at the point of thematic saturation, or when no
new insights are gleaned from the interviews.
Analysis
Power and sample size
For the CE aims, we conservatively expect 500,000
patients with GERD and 20,000 BE patients in our study
cohort. Using the estimated number of BE patients, an
average annual EA rate in BE of 0.5%, and an average
follow up for BE patients of 5 years, we expect to find at
least 500 EA cases in the context of an existing BE. We
assume based on preliminary work that approximately
33% will have a surveillance endoscopy every 2 years,
33% have a surveillance endoscopy every 3 years, and
33% will have no endoscopy. The favorable outcomes in
the 2-year surveillance group will be early stage EA diag-
nosis for 30% of cases, EA curative treatment in 25%,
and 3-year survival in 50%. Since there are 3 compari-
sons we set alpha = 0.025 and power = 0.80. Therefore, with
166 patients in each group, we will be able to detect differ-
ences of (50% vs. 34%), (30% vs. 15%), and (25% vs. 12%) in
any of the outcomes between the every 2 year surveillance
and no surveillance groups.
Sample size estimates for the qualitative aim will be
based on established principles of thematic saturation.
We will conclude sampling for each subgroup at the
point of thematic saturation for each patient group [33].
We will assume thematic saturation when all coders
agree that three consecutive transcripts from each pa-
tient group render no new insights. We will also estab-
lish thematic saturation for physicians as a distinct
group and continue recruitment and coding until all
coders agree that three consecutive transcripts are satu-
rated across all major themes.
Data analysis for the CE aims
We will calculate the cumulative and yearly EA inci-
dence rates overall and in groups stratified by disease
status (GERD with or without BE) and endoscopy status
(screening, surveillance, none); we will also calculate in-
cidence rate ratios (and 95% CI). The main comparison
groups are (screening vs. no screening) and (surveillance
every 2 years or surveillance every 3 years vs. no surveil-
lance). Similar comparisons will be made for the propor-
tions of patients with early EA stage and whether they
received EA treatment. We will examine patient and
non-patient predictors that may serve as clinically or
epidemiologically useful predictors of the study out-
comes. For EA stage and treatment receipt, we will use
logistic regression models. For survival, we will use mul-
tivariable hierarchical Cox proportional hazards model-
ing to assess the effect of screening or surveillance on
mortality risk while adjusting for patient and non patient
features.
We will use propensity score matching to adjust for
the non-random probability of receiving endoscopic
screening or surveillance. We will use logistic regression
analyses to determine the probability (propensity score)
of receiving screening endoscopy based on patient and
non-patient factors detailed above, and match the sub-
jects receiving screening with those who did not receive
screening based on the propensity score.
Analysis for the qualitative aim
We will analyze in-depth interview data using principles
of framework analysis, which allows for the inclusion of
existing concepts as well as emergent themes [34]. The
advantage of framework analysis is that it provides a
clear and systematic approach to managing and analyz-
ing large quantities of complex data. This approach
allows themes to develop both from the research ques-
tions and from the narratives of research participants. In
this way, our analysis will apply both inductive and de-
ductive methods. There are five stages in framework
analysis: familiarization, identification of a thematic
framework, indexing (coding), charting themes, and map-
ping and interpretation (See Additional file 1: Appendix IV
for coding framework).
Two independent coders with experience in frame-
work analysis will independently create codes and index
the data using the software package Atlas. ti 5.0. We will
use the constant comparative method of data interpret-
ation, which involves making comparisons at every stage
of the analysis [35]. For instance, we will compare earlier
data with later data, interviews conducted by different
interviewers, and a priori themes with emergent themes.
Our coding procedure will involve several steps. First,
coders will become familiarized with all the data by
reading, rereading, and summarizing each transcript.
Each transcript will be supplemented with observational
notes, which will allow us to gain an overall impression
of the interviews and focus group, and to identify “key
ideas and recurrent themes” about BE and endoscopy
[34]. Based on these insights, coders will begin creating
an overall thematic framework, incorporating both
emergent and a priori themes from our conceptual
model. The research team will discuss this framework
and develop a coding scheme. In order to reduce bias
and ensure inter-coder reliability and the utility of the
codes, two members of the research team will independ-
ently code 6 transcripts [36]. We will identify inconsist-
encies and emergent ideas, and modify the coding
manual accordingly. Two coders will then systematically
apply the thematic framework to all transcripts. During
this indexing procedure, coders will add and modify
the coding scheme as necessary. We will chart common-
alities and divergent themes within and among all par-
ticipant subcategories. We will merge coded transcripts
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in Atlas. ti and the team will review the data. Disagree-
ments about coding decisions will be resolved through
group consensus [36]. Finally, we will use the thematic
framework to chart the themes across focus groups to
identify saliency and compare and contrast participants’
accounts to identify meaningful associations and pat-
terns in the data (mapping and interpretation). Once the
data are organized and thematically related, we will iden-
tify a central category that best summarizes the relation-
ships observed in the data.
Triangulation of data
We expect wide variations in the utilization of endo-
scopic screening and surveillance with predominant
findings of underutilization as well as some overutiliza-
tion likely driven by small-area variations in the supply of
endoscopic services. In additional to descriptive results on
a healthcare system wide basis, quantitative analysis may
provide needed evidence regarding the benefits of screen-
ing on outcomes of interest (mortality, stage at diagnosis,
increased use of surveillance following screening, etc), and
key data to inform outcome expectancies of surveillance
endoscopy (i.e. which surveillance interval is likely to im-
prove mortality and recognition of dysplasia progression).
We also expect that several quantifiable and potentially
modifiable patient, provider, and facility factors will be
predictive of receipt (or non receipt) of endoscopy.
As in most observational studies, we expect that these
quantitative analyses will explain only a small proportion
of the variations in practice. Our implicit chart EMR re-
view in selected groups of patients will help maximize
the collection of variables and thus increase the
explained portion of variation. However, we believe that
most of the variation cannot be explained by physio-
logical factors that can be quantified by the databases,
and therefore our qualitative aim will offer insight into
how physicians’ perceptions and biases shape their deci-
sions regarding endoscopy, as well as how patients’ per-
ceptions of cancer risk, their expected outcomes of
participation, and by other affective responses to screen-
ing and surveillance guide their decisions to participate
in screening and surveillance. We expect that in certain
subgroups the CE of endoscopic screening and especially
surveillance will be favorable, but as described above,
widely misutilized. As is common in qualitative research,
our findings are most likely to generate themes related
arising from responses to our interview guides. Inter-
pretation of thematic data is valuable but often highly
contextual. To improve the generalizability of our data,
we will attempt to place our qualitative themes within
the framework of contemporary psychological models of
decision making and health behavior [37,38]. Within this
framework, our qualitative findings will help to inform
where key gaps remain in the decision making process
to pursue screening and surveillance. Additional analyses
can be planned to address these gaps, at least partially, if
the data is available.
The next logical step is to implement strategies to cor-
rect the utilization of endoscopic screening and surveil-
lance. The findings of the qualitative aim will be crucial
in designing these interventions, particularly if most the
practice variations cannot be attributed to patient related
clinical factors. Informed by the findings of our quantita-
tive results, additional qualitative interviews with patients
and physicians will explore the comparative acceptability
of alternative screening and surveillance protocols. These
findings will provide insights into the adoption and imple-
mentation of revised guidelines for endoscopic screening
and surveillance.
Results and discussion
A tremendous amount of resources are spent each year on
performing endoscopic procedures to screen and survey for
BE to prevent EA; however, there is limited knowledge
about the effectiveness of various EA screening and surveil-
lance strategies, and even less is known about factors that
shape physicians’ and patients’ decisions concerning the
adoption and implementation of these strategies.
The aims of this CE study are to generate a better
understanding of particular patterns of endoscopy (fre-
quency and risk factors) that are associated with tangible
benefits in terms of reducing the incidence or mortality
from EA. We will provide insight into physicians’ deci-
sions to perform screening, surveillance, and treatment
procedures, and adherence (or not) to recommended
guidelines. Additionally, we will gain a better under-
standing of affective and structural factors that shape
patients’ risk perceptions and decisions to adhere to can-
cer screening and surveillance guidelines. Ultimately,
our findings have the potential to inform evidence-based
guidelines and clinical practice.
CE research is not a new concept and there is criti-
cism regarding its ability to impact routine clinical care
[39]. The American Recovery and Reinvestment Act
(2009) and Patient Protection and Affordable Care Act
(2010) provided substantial new investments in CE re-
search. As a response, the Methodology Committee of
the Patient-Centered Outcomes Research Institute—
itself funded by the Affordable Care Act, created a set
of methodological standards for conducting “patient-
centered” CE research [40]. The four standards include
1) prioritizing research questions, 2) using appropriate
study designs and analyses, 3) incorporating patient
perspectives, and 4) fostering efficient dissemination
and implementation of results. Our proposed CE study
of screening and surveillance endoscopy is likely to in-
form policy and practice because the study aligns with the
four standards articulated by the PCORI committee. First,
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we have prioritized our research aims on the key clinical
questions facing physicians and patients regarding endo-
scopic screening and surveillance. As part of the study, we
begin with qualitative interviews with patients and physi-
cians to clarify the knowledge and perception gaps that
hamper good decision making. The results of these inter-
views will shape the quantitative analyses. Second, we use
appropriate study designs and analytical approaches to
avoid biases and errors common to observational studies.
We use a structured chart review to improve the validity
and reliability of our outcome definitions. Furthermore,
we use specialized analytical techniques (i.e. propensity
score matching) to reduce bias in our analytical models
[41]. Third, patients are engaged throughout the research
process to inform the identification of key clinical ques-
tions, interpretation of research findings, and the potential
adoption and implementation of guideline recommen-
dations arising from study conclusions. In particular,
we will frame the input received from patients within
models of decision making and health behavior as they
relate to screening and surveillance endoscopy. It is
through this modeling that key clinical questions arise
and research findings can be easily interpreted into
patient-physician decisions. Finally, our study fosters ef-
ficient adoption and implementation of results through
the involvement of practicing physicians throughout the
study process. As with patients, we interview physicians
to inform our key clinical questions and to interpret
the findings within everyday clinical contexts. The in-
volvement of patients and physicians throughout the
study dramatically improves the real-world relevance of
the study findings and enhances their likelihood for
adoption and implementation in routine care.
Conclusions
The proposed CE study is consistent with the Patient Cen-
tered Outcomes Research Institute (PCORI) methodo-
logical standards for CE research. The current study is
consistent with the principle of patient-centeredness by
using a mixed-methods approach that includes in-depth
qualitative interviews with physicians and patients who are
intimately involved with the questions of screening and
surveillance endoscopy. Qualitative methods are used to
improve the clinical relevance and patient-centeredness of
the research questions and findings. The study includes the
largest national sample of patients undergoing screening/
surveillance endoscopy and uses appropriate study designs
and analyses. In summary, the proposed CE study has the
real potential to impact policy and practice through its
conformity with the PCORI methodological standards for
patient-centered CE research.
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